A PHASE 1 TRIAL OF CUDC-907, AN ORAL, FIRST-IN-CLASS, DUAL INHIBITOR OF HDAC AND PI3K, IN PATIENTS WITH REFRACTORY OR RELAPSED LYMPHOMA AND MULTIPLE MYELOMA
EHA Library, Yasuhiro Oki,
100569
APREPITANT PREVENTS NAUSEA AND VOMITING AFTER A HIGH-EMETOGENIC DOSE OF CYCLOPHOSPHAMIDE FOR PBSC HARVESTING: A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
EHA Library, Leonardo Flenghi,
100629
COST EFFECTIVENESS OF BORTEZOMIB, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN AND PREDNISONE FOR THE FIRST-LINE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION
EHA Library, Marjolijn van Keep,
100656
IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY
EHA Library, Paula Cramer,
101332